MARCH 18-22, 1995
86th Annual Meeting
Chairpersons: Donald S. Coffey, Baltimore, MD
Metro Toronto Convention Centre, Toronto, Ontario, Canada

APRIL 1-6, 1995
Signal Transduction of Normal and Tumor Cells
Co-sponsored by the National Cancer Institute of Canada
Chairpersons: Anthony J. Pawson, Toronto, Ontario, Canada; André Veillette, Montreal, Quebec, Canada; Grant McFadden, Edmonton, Alberta, Canada
Banff Centre, Banff, Alberta, Canada

OCTOBER 14-18, 1995
Cytokines and Cytokine Receptors
Chairperson: Steven Gillis, Seattle, WA
The Sagamore, Bolton Landing (Lake George), NY

NOVEMBER 5-9, 1995
Cancer: The Interface Between Basic and Applied Research
Chairpersons: Bert Vogelstein, Baltimore, MD; Stephen H. Friend, Seattle, WA; John D. Minna, Dallas, TX
Stouffer Harborside Hotel, Baltimore, MD

NOVEMBER 17-21, 1995
Novel Strategies Against Resistant Cancers
Chairpersons: Victor Ling, Toronto, Ontario, Canada; Daniel D. Von Hoff, San Antonio, TX
Sanibel Harbour Resort & Spa, Ft. Myers, FL

DECEMBER 2-6, 1995
The Molecular Basis of Gene Transcription
Chairperson: Tom Curran, Nutley, NJ
Hotel Del Coronado, Coronado (San Diego), CA

JANUARY 17-20, 1996
Cancer and the Cell Cycle
Joint Meeting with the Swiss Institute for Experimental Cancer Research
Chairpersons: Edward E. Harlow, Charlestown, MA; Viesturs Simanis, Lausanne, Switzerland
Location to be Announced in Lausanne, Switzerland

FEBRUARY 19-25, 1996
Cancer Susceptibility Genes and Molecular Carcinogenesis
Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC
Keystone Resort, Keystone, CO

MARCH 1996
Proteases and Their Inhibitors in Cancer
Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI
Location to be Announced

APRIL 20-24, 1996
87th Annual Meeting
Chairperson: Lorraine J. Gudas, New York, NY
Washington D.C. Convention Center, Washington, D.C.

JUNE 1996
Inducible Genomic Responses
Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Birmingham, England; Richard I. Morimoto, Evanston, IL
Location to be Announced

OCTOBER 1996
Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France
Location to be Announced in Budapest, Hungary

OCTOBER 19-23, 1996
Programmed Cell Death
Chairperson: Stanley J. Korsmeyer, St. Louis, MO
The Sagamore, Bolton Landing (Lake George), NY

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
SANDOZ
Post-Doctoral Fellowship in Molecular Toxicology

The division of Pathology and Toxicology of the American Health Foundation has an opening for a post-doctoral fellow for one or two years to study molecular effects of pharmaceuticals in relation to their potential hazard to humans. The division has a broad-based program on chemical safety assessment involving research on peroxisome proliferators, antioxidants, antiestrogens and quinolone antibiotics. The laboratory utilizes in vivo, in vitro, biochemical and molecular techniques in these studies. The stipend for the fellowship is $25,000 or greater, depending upon qualifications. Candidate should be a highly qualified recent graduate with experience in molecular techniques.

The American Health Foundation is a not-for-profit biomedical research organization with a staff of over 200 devoted to disease prevention. The laboratory of the Foundation is located on the campus of the New York Medical College, which is nearby to White Plains and convenient to New York City.

Inquiries should be addressed to:
Gary M. Williams, M.D., Director of Medical Sciences
American Health Foundation
1 Dana Road, Valhalla, New York 10595
EEO/M/F/H/V/ADA

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)

SPECIAL OPPORTUNITIES FOR YOUNG INVESTIGATORS

The AACR is a professional society of over 10,000 scientists and physicians involved in cancer research. Special opportunities for young investigators include:

• Associate Membership conferring almost all of the benefits of regular membership at reduced rates

• Employment Register listing available positions and candidates in all subdisciplines of cancer research. Listings appear in several issues of Cancer Research, and interviews are arranged at the AACR Annual Meeting (Toronto, Ontario, Canada, March 18-22, 1995)

• Travel Grants to the Annual Meeting and AACR Special Conferences

• Mentorship Program and Special Travel Awards for NCI-designated minority scientists

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 10,000 scientists and physicians involved in cancer research. Members in the AACR enjoy

• subscriptions to the journals Cancer Research, Cell Growth & Differentiation (CG&D), Cancer Epidemiology, Biomarkers & Prevention, and (starting in 1995) Clinical Cancer Research at reduced member rates

• early notification of and reduced registration rates at the AACR Annual Meeting and Special Conferences

• Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

• Mentorship Program

• Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313

EPIDEMIOLOGIST

Dartmouth Medical School seeks an epidemiologist with a primary research focus on the biology and/or genetics of cancer. This position will be tenure track in the Section of Biostatistics and Epidemiology of the Department of Community and Family Medicine. The position will involve affiliation with the Norris Cotton Cancer Center, an NCI-designated comprehensive cancer center.

An appointment will be made at a level commensurate with past productivity and experience. Responsibilities will include the conduct of biologically-oriented epidemiological studies of cancer, and participation in the teaching functions of Dartmouth Medical School.

Requirements are:

1. A Ph.D. in Epidemiology, or an M.D. with equivalent research experience;

2. At least 3 years experience in biologically-oriented epidemiological research regarding cancer;

3. A publication record in peer-reviewed journals and demonstrated ability for significant research.

Submit a CV with publications list and names of 3 references by March 1, 1995 to:

John A. Baron, M.D.
Department of Community and Family Medicine
HB 7927, Dartmouth Medical School
Hanover, NH 03755-3861

Dartmouth Medical School is an equal opportunity-affirmative action employer. Women and minorities are encouraged to apply.
The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

June 30-July 6, 1995
The Given Institute
Aspen, Colorado

ORGANIZERS

STEPHEN H. FRIEND
Fred Hutchinson Cancer Research Center
Seattle, WA

L. MICHAEL GLODE
University of Colorado School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University School of Medicine
Nashville, TN

STEPHEN H. FRIEND
Fred Hutchinson Cancer Research Center
Seattle, WA

L. MICHAEL GLODE
University of Colorado School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University School of Medicine
Nashville, TN

• Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology such as gene therapy, oncogenes and growth factors, tumor suppressor genes, fusion proteins, genetic mutations, antisense, metastasis, and drug resistance.

• Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.

• A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.

• Financial support for participants who are physicians in training or oncology fellows.

• Category I CME credits through the University of Colorado School of Medicine.

Faculty

Lectures

STEPHEN H. FRIEND/ Seattle, WA
MICHAEL B. KASTAN/ Baltimore, MD
ANDRÉ BERNARDS/ Charlestown, MA
HAROLD L. MOSES/ Nashville, TN
TYLER JACKS/ Cambridge, MA
ROBERT EISENMAN/ Seattle, WA

A. THOMAS LOOK/ Memphis, TN
THEA D. TLSTY/ Chapel Hill, NC
ALLEN L. OLIFF/ West Point, PA
DADIA ROSEPINAL/ Charlestown, MA
ERIC R. FEARON/ New Haven, CT
L. MICHAEL GLODE/ Denver, CO

PATRICIA S. STEEG/ Bethesda, MD
MARC E. LIPPMAN/ Washington, DC
JENNIFER A. PIETENPOL/ Nashville, TN
CALVIN B. HARLEY/ Menlo Park, CA
JACQUELINE A. LEES/ Charlestown, MA
KATHLEEN R. CHO/ Baltimore, MD

Additional Speakers to be Announced

Laboratory Rotations

DAVID LANDSMAN/ Bethesda, MD. "Computer Searching in Molecular Biology."
ANDREW LIU/ Denver, CO. "Polymerase Chain Reaction Technology."
JAMES P. HOEFFLER/ Denver, CO. "Transfer of Nucleic Acids and Proteins."
MARILEILA V. GARCIA/ Denver, CO. "Practical Cytogenetics."
(INSTRUCTOR TO BE ANNOUNCED) "Gene Expression Systems."

Application Deadline March 27, 1995

For further information, contact
American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
Alan C. Sartorelli has been a leader in many facets of cancer research for more than 36 years, as evidenced by his 400 publications, which have dealt with areas ranging from the development of new therapeutic agents and regimens to fundamental studies on the neoplastic state. Dr. Sartorelli received his B.S. training in pharmacy at Northeastern University and an M.S. in Chemistry from Middlebury College. He completed his doctoral research with G. A. LePage at the McArdle Institute for Cancer Research of the University of Wisconsin. After a brief period at the Samuel Roberts Nobel Foundation in Oklahoma, he was appointed to the faculty of the Department of Pharmacology at the Yale University School of Medicine where he became Professor in 1967 and was named the first Alfred Gilman Professor of Pharmacology in 1987. He served as Chairman of the Department from 1977 to 1984 and subsequently led the Yale Comprehensive Cancer Center as Director from 1984 to 1993.

His laboratory has been responsible for defining many aspects of purine nucleotide metabolism and its control by antimitabolites. Particularly notable are the elucidation of the mechanism of resistance to agents such as 6-thioguanine and azaserine and the development of the concept of complementary inhibition as an approach to combination chemotherapy. His research on bioreductive alkylating agents and their application to the treatment of X-ray refractory hypoxic tumor cells has evolved into a valuable therapeutic regimen for the combined therapy of head and neck cancer.

In a broad program of synthesis and biological studies, a series of thiosemicarbazone derivatives was developed as ribonucleotide reductase inhibitors. During the 1970s, his group initiated studies with potential differentiating agents as a new approach to cancer therapy. These studies have defined some of the alterations in cell surface and nuclear structure, as well as function during the differentiation of murine erythroleukemia. These studies have been extended to investigations of the mechanisms involved in the initiation of HL-60 and WEHI-3B leukemia cells and of other neoplastic cell lines by a variety of anticancer agents, as well as by natural products, such as vitamin D3 and retinoic acid. In a related program, the induction of differentiation of leukemia cells was demonstrated by purine analogues that did not interfere with the purine nucleotide biosynthetic pathways but interacted with surface receptors for benzodiazepines. More recently, the effects on growth and differentiation of factors such as granulocyte colony-stimulating factor, transforming growth factor β, and epidermal growth factor, as well as controls on the expression of the transferrin receptor, were examined by his laboratory. Extending these studies, Dr. Sartorelli and his team have developed a series of alkylating agent prodrugs with potent antineoplastic and antitrypanosomal activity.

As Director of the Yale Comprehensive Cancer Center, he was instrumental in the organization and implementation of one of the earliest mobile mammography vans programs. This has provided screening for more than 40,000 women in Connecticut. At the national level, he has been a creative contributor to the programs of the National Cancer Institute as a member and chairperson of numerous committees and advisory bodies.

His leadership in biomedical research has been recognized by his service as President of the American Association for Cancer Research (AACR) in 1986–87 and as President of the Association of American Cancer Institutes in 1987. During his term as AACR President, Dr. Sartorelli spearheaded many initiatives, most notable of which was the launch of the Association’s Special Conferences in Cancer Research, a thriving program which has experienced continued expansion and increased popularity since its inception.

He has received many honors, including the American Society for Pharmacology and Experimental Therapeutics Award in Experimental Therapeutics in 1986 and the Mike Hogg Award in 1989, and he was elected to membership in the Institute of Medicine in 1987.

Over the years, he has made many important contributions to the publication of cancer and pharmacology research as editor of three journals and as a member of the editorial board of 18 journals, including Cancer Research. Particularly notable have been his roles as Executive Editor of Biochemical Pharmacology and as founding editor of Pharmacology and Therapeutics and Oncology Research. Moreover, his propensity and vision for scientific publishing were great assets to the Association during his tenure as Chairperson of the Publications Committee from 1981–88.

In those rare moments when not engaged in aspects of science, Dr. Sartorelli pursues his primary avocation of music and opera, serving as chairman of the Shubert Opera Board in New Haven and as a student of voice and guitar.

We are indebted to Robert Handschumacher for information for this legend and for the cover photograph.

Sidney Weinhouse